Fulzerasib is a potent pyrazolo[3,4-d]pyrimidine derivative that functions as a selective inhibitor of the farnesyl transferase enzyme, playing a critical role in oncology research for treating solid tumors… Read more
Fulzerasib is a potent pyrazolo[3,4-d]pyrimidine derivative that functions as a selective inhibitor of the farnesyl transferase enzyme, playing a critical role in oncology research for treating solid tumors associated with RAS signaling pathway activation. By blocking the post-translational modification of RAS proteins, this compound effectively inhibits cell proliferation in various cancer types, including non-small cell lung cancer and pancreatic adenocarcinoma. Laboratories utilize high-purity Fulzerasib reference standards to perform rigorous impurity profiling and method validation during drug development. Additionally, stable isotope labelled compounds such as Fulzerasib-13C-d3 serve as essential internal standards for quantitative analysis and quality control, ensuring accuracy in complex bioanalytical procedures involving mass spectrometry. These research tools are indispensable for pharmaceutical scientists engaged in characterizing the drug's metabolic pathways and maintaining consistent quality standards throughout the analytical testing process.